Introduction en Bourse de TxCell sur Euronext Paris


Paris –14 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs[1], today congratulated TxCell, a French biotechnology company specialising in immunotherapies for the treatment of chronic inflammatory and auto-immune diseases, on its listing. TxCell joined Euronext’s regulated market in Paris (compartment C).

Founded in 2001, TxCell is a biopharmaceutical company based in Sophia Antipolis in southern France. It is developing a new generation of personalised cell-based immunotherapies that use the patient’s own cells to treat severe chronic inflammatory and auto-immune diseases. Through its patented production process, TxCell makes this type of cell therapy economically viable for the first time. Its first candidate drug Ovasave®, now in clinical development, targets patients suffering from Crohn’s disease who are refractory to existing treatments—an estimated 80,000 to 100,000 people a year representing a potential market estimated at around €3 billion. The company’s second candidate drug is Col-Treg, now under development for the treatment of auto-immune uveitis, a rare disease that is one of the main causes of blindness in the industrialised world and whose sufferers currently have a very limited range of therapeutic options.

TxCell (ticker symbol: TXCL) was listed through the admission to trading of 7,860,467 existing shares making up the company’s equity and 2.903.226 new shares issued under a Global Offering[2].

The admission and issue price of TxCell shares was set at €5.58 per share. The company’s market capitalisation stands at around €63.6 million and a total €16.2 million was raised.

Eric Forest, Chairman and CEO of EnterNext, said: “We welcome TxCell, the seventh life sciences company to join Euronext markets since the beginning of the year. Innovative companies are structures with major growth potential. EnterNext’s aim is to promote the range of financing solutions available on the Bourse and encourage contacts between investors and these companies that are seeking the resources they need to pursue development.”

Damian Marron, TxCell’s Chief Executive Officer, added: “I am delighted with TxCell’s successful listing on Euronext, where the segment dedicated to health-related companies has grown steadily and increased its international reach. I would like to thank our historical shareholders Bpifrance and all of those who have joined our innovative and unique drive to improve the lives of thousands of patients suffering from inflammatory and auto-immune illnesses such as Crohn’s disease.”

[1]Small and medium-sized entreprises
The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2023, Euronext N.V. - All rights reserved.